カテゴリ： Allied Market Research, 世界, 医療/バイオ

クリ・デュ・チャット症候群治療のグローバル市場（2021〜2031）：理学療法、言語療法、作業療法

■ 英語タイトル：Cri-du-chat Syndrome Treatment Market By Treatment (Physiotherapy, Speech therapy, Occupational therapy), By End User (Hospitals and specialty clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031

調査会社Allied Market Research社が発行したリサーチレポート（データ管理コード：ALD23FB269）■ 発行会社/調査会社：Allied Market Research
■ 商品コード：ALD23FB269
■ 発行日：2022年10月
■ 調査対象地域：グローバル
■ 産業分野：医療
■ ページ数：148
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後24時間以内）
■ 販売価格オプション（消費税別）
Online Only（1名閲覧、印刷不可）USD3,570 ⇒換算￥542,640見積依頼/購入/質問フォーム
Single User（1名閲覧）USD5,730 ⇒換算￥870,960見積依頼/購入/質問フォーム
Enterprise User（閲覧人数無制限）USD9,600 ⇒換算￥1,459,200見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Allied Market Research社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[クリ・デュ・チャット症候群治療のグローバル市場（2021〜2031）：理学療法、言語療法、作業療法]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

Allied Market Research社の本市場調査レポートでは、2021年に1,332.46千ドルであった世界のクリ・デュ・チャット症候群治療市場規模が、2031年までに1,918.21千ドルに到達し、2022年から2031年にかけてCAGR（年平均成長率）3.7%で成長すると予測しています。本レポートは、クリ・デュ・チャット症候群治療の世界市場を総合的に調査・分析した資料であり、イントロダクション、エグゼクティブサマリー、市場概要、治療別（理学療法、言語療法、作業療法）分析、エンドユーザー別（病院・専門クリニック、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米・中東・アフリカ）分析、企業状況、企業情報などを掲載しています。また、本レポートは、Hoppers Physio、Chatham Speech and Myo、Movement Masters Physical Therapy、Rio Children's Hospital、Blossoms Physiotherapy、Institute for Child Developmentなどの企業情報を含んでいます。
・イントロダクション
・エグゼクティブサマリー
・市場概要
・世界のクリ・デュ・チャット症候群治療市場規模：治療別
- 理学療法における市場規模
- 言語療法における市場規模
- 作業療法における市場規模
・世界のクリ・デュ・チャット症候群治療市場規模：エンドユーザー別
- 病院・専門クリニックにおける市場規模
- その他における市場規模
・世界のクリ・デュ・チャット症候群治療市場規模：地域別
- 北米のクリ・デュ・チャット症候群治療市場規模
- ヨーロッパのクリ・デュ・チャット症候群治療市場規模
- アジア太平洋のクリ・デュ・チャット症候群治療市場規模
- 中南米・中東・アフリカのクリ・デュ・チャット症候群治療市場規模
・企業状況
・企業情報

世界のクリ・デュ・チャット症候群治療市場は、2021年には133.24万ドルと評価され、2031年には191.82万ドルに達すると予測され、2022年から2031年までの年平均成長率は3.7%です。

クリ・デュ・チャット症候群は、5p-症候群や猫の鳴き声症候群としても知られ、5番染色体の短腕（p腕）から遺伝物質が欠失することによってもたらされるまれな遺伝性疾患です。この異常な染色体欠損は原因不明です。泣き声が甲高く、頭が小さく、鼻梁が扁平なのが、クリ・デュ・チャット症候群の赤ちゃんの特徴です。
およそ5万人に1人がこの病気にかかっていると推定されています。この推定値は減少傾向にあります。より精巧で定期的な遺伝子検査が行われるようになり、より軽症の症例が多く発見されるようになったため、25,000人に1人という低い割合になるかもしれません。このように、クリ・デュ・チャット症候群の有病率の高さは、遺伝性疾患の診断の増加とともに、市場成長の原動力となっています。

この症候群は特に薬理学的な治療法がありません。子供の潜在能力を最大限に引き出すためには、この遺伝性疾患を持って生まれた子供には、両親、セラピスト、医療・教育の専門家からなるチームによる継続的なケアが必要でしょう。早期から一貫した理学療法、作業療法、言語療法を行うことで、潜在能力を最大限に引き出し、充実した生活を送ることができます。また、理学療法、作業療法、言語療法に関する認知度や利点の増加が市場を牽引する主な要因です。疾病の蔓延と自己負担支出の増加は、医療費の大幅な上昇につながっています。これらの要因が市場の成長を促進しています。
しかし、治療に伴う高コストが市場成長の妨げになると予想されます。逆に、消費者の需要を満たす新興市場の成長機会は、投資家にとって同市場への大きな投資機会となることが期待されます。

クリ・デュ・チャット症候群治療市場は、治療法、エンドユーザー、地域によって細分化されます。治療法別では、市場は理学療法、言語療法、作業療法に分類されます。エンドユーザー別では、病院・専門クリニック、その他に分類されます。地域別では、北米、欧州、アジア太平洋、ラテンアメリカ、中東、アフリカ（LAMEA）に市場を分けて分析しています。

本レポートに掲載されている主要企業は、Hoppers Physio、Jeevam Therapy、Physiocomestoyou、EURO-THERAPIES、Institute for Child Development、Blossoms Physiotherapy、Pediatric Advanced Therapy、Chatham Speech and Myo、Movement Masters Physical Therapy、Rio Children’s Hospitalです。

〈ステークホルダーにとっての主なメリット〉
・本レポートは、2021年から2031年までのクリ・デュ・チャット症候群治療市場分析の市場セグメント、現在の動向、予測、ダイナミクスを定量的に分析し、クリ・デュ・チャット症候群治療市場の有力な市場機会を特定します。
・主要な促進要因、阻害要因、機会に関する情報とともに市場調査を提供します。
・ポーターのファイブフォース分析により、バイヤーとサプライヤーの潜在力を明らかにし、ステークホルダーが利益重視のビジネス決定を行い、サプライヤーとバイヤーのネットワークを強化できるようにします。
・クリ・デュ・チャット症候群治療市場のセグメンテーションを詳細に分析することで、市場機会を見極めることができます。
・各地域の主要国を世界市場への収益貢献度に応じてマッピングしています。
・市場プレイヤーのポジショニングはベンチマーキングを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
・地域別および世界のクリ・デュ・チャット症候群治療市場動向、主要企業、市場セグメント、応用分野、市場成長戦略の分析を含みます。

〈主要市場セグメント〉
治療法別
理学療法
言語療法
作業療法

エンドユーザー別
病院・専門クリニック
その他

地域別
・北米
米国
カナダ
メキシコ
・ヨーロッパ
ドイツ
フランス
イギリス
イタリア
スペイン
その他のヨーロッパ
・アジア太平洋
日本
中国
インド
オーストラリア
韓国
その他のアジア太平洋地域
・LAMEA
ブラジル
サウジアラビア
南アフリカ
その他のLAMEA地域

〈主要市場プレイヤー〉
Hoppers Physio
Chatham Speech and Myo
Movement Masters Physical Therapy
Rio Children’s Hospital
Blossoms Physiotherapy
Institute for Child Development
Pediatric Advanced Therapy
EURO-THERAPIES
Physiocomestoyou
Jeevam Therapy

世界の市場調査レポート販売サイト（H&Iグローバルリサーチ株式会社運営）
*** レポート目次（コンテンツ）***

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT
4.1 Overview
4.1.1 Market size and forecast
4.2 Physiotherapy
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market share analysis by country
4.3 Speech therapy
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market share analysis by country
4.4 Occupational therapy
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market share analysis by country
CHAPTER 5: CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER
5.1 Overview
5.1.1 Market size and forecast
5.2 Hospitals and specialty clinics
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market share analysis by country
5.3 Others
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market share analysis by country
CHAPTER 6: CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY REGION
6.1 Overview
6.1.1 Market size and forecast
6.2 North America
6.2.1 Key trends and opportunities
6.2.2 North America Market size and forecast, by Treatment
6.2.3 North America Market size and forecast, by End User
6.2.4 North America Market size and forecast, by country
6.2.4.1 U.S.
6.2.4.1.1 Key market trends, growth factors and opportunities
6.2.4.1.2 Market size and forecast, by Treatment
6.2.4.1.3 Market size and forecast, by End User
6.2.4.2 Canada
6.2.4.2.1 Key market trends, growth factors and opportunities
6.2.4.2.2 Market size and forecast, by Treatment
6.2.4.2.3 Market size and forecast, by End User
6.2.4.3 Mexico
6.2.4.3.1 Key market trends, growth factors and opportunities
6.2.4.3.2 Market size and forecast, by Treatment
6.2.4.3.3 Market size and forecast, by End User
6.3 Europe
6.3.1 Key trends and opportunities
6.3.2 Europe Market size and forecast, by Treatment
6.3.3 Europe Market size and forecast, by End User
6.3.4 Europe Market size and forecast, by country
6.3.4.1 Germany
6.3.4.1.1 Key market trends, growth factors and opportunities
6.3.4.1.2 Market size and forecast, by Treatment
6.3.4.1.3 Market size and forecast, by End User
6.3.4.2 France
6.3.4.2.1 Key market trends, growth factors and opportunities
6.3.4.2.2 Market size and forecast, by Treatment
6.3.4.2.3 Market size and forecast, by End User
6.3.4.3 UK
6.3.4.3.1 Key market trends, growth factors and opportunities
6.3.4.3.2 Market size and forecast, by Treatment
6.3.4.3.3 Market size and forecast, by End User
6.3.4.4 Italy
6.3.4.4.1 Key market trends, growth factors and opportunities
6.3.4.4.2 Market size and forecast, by Treatment
6.3.4.4.3 Market size and forecast, by End User
6.3.4.5 Spain
6.3.4.5.1 Key market trends, growth factors and opportunities
6.3.4.5.2 Market size and forecast, by Treatment
6.3.4.5.3 Market size and forecast, by End User
6.3.4.6 Rest of Europe
6.3.4.6.1 Key market trends, growth factors and opportunities
6.3.4.6.2 Market size and forecast, by Treatment
6.3.4.6.3 Market size and forecast, by End User
6.4 Asia-Pacific
6.4.1 Key trends and opportunities
6.4.2 Asia-Pacific Market size and forecast, by Treatment
6.4.3 Asia-Pacific Market size and forecast, by End User
6.4.4 Asia-Pacific Market size and forecast, by country
6.4.4.1 Japan
6.4.4.1.1 Key market trends, growth factors and opportunities
6.4.4.1.2 Market size and forecast, by Treatment
6.4.4.1.3 Market size and forecast, by End User
6.4.4.2 China
6.4.4.2.1 Key market trends, growth factors and opportunities
6.4.4.2.2 Market size and forecast, by Treatment
6.4.4.2.3 Market size and forecast, by End User
6.4.4.3 India
6.4.4.3.1 Key market trends, growth factors and opportunities
6.4.4.3.2 Market size and forecast, by Treatment
6.4.4.3.3 Market size and forecast, by End User
6.4.4.4 Australia
6.4.4.4.1 Key market trends, growth factors and opportunities
6.4.4.4.2 Market size and forecast, by Treatment
6.4.4.4.3 Market size and forecast, by End User
6.4.4.5 South Korea
6.4.4.5.1 Key market trends, growth factors and opportunities
6.4.4.5.2 Market size and forecast, by Treatment
6.4.4.5.3 Market size and forecast, by End User
6.4.4.6 Rest of Asia-Pacific
6.4.4.6.1 Key market trends, growth factors and opportunities
6.4.4.6.2 Market size and forecast, by Treatment
6.4.4.6.3 Market size and forecast, by End User
6.5 LAMEA
6.5.1 Key trends and opportunities
6.5.2 LAMEA Market size and forecast, by Treatment
6.5.3 LAMEA Market size and forecast, by End User
6.5.4 LAMEA Market size and forecast, by country
6.5.4.1 Brazil
6.5.4.1.1 Key market trends, growth factors and opportunities
6.5.4.1.2 Market size and forecast, by Treatment
6.5.4.1.3 Market size and forecast, by End User
6.5.4.2 Saudi Arabia
6.5.4.2.1 Key market trends, growth factors and opportunities
6.5.4.2.2 Market size and forecast, by Treatment
6.5.4.2.3 Market size and forecast, by End User
6.5.4.3 South Africa
6.5.4.3.1 Key market trends, growth factors and opportunities
6.5.4.3.2 Market size and forecast, by Treatment
6.5.4.3.3 Market size and forecast, by End User
6.5.4.4 Rest of LAMEA
6.5.4.4.1 Key market trends, growth factors and opportunities
6.5.4.4.2 Market size and forecast, by Treatment
6.5.4.4.3 Market size and forecast, by End User
CHAPTER 7: COMPANY LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Key developments
CHAPTER 8: COMPANY PROFILES
8.1 Hoppers Physio
8.1.1 Company overview
8.1.2 Company snapshot
8.1.3 Operating business segments
8.1.4 Product portfolio
8.1.5 Business performance
8.1.6 Key strategic moves and developments
8.2 Jeevam Therapy
8.2.1 Company overview
8.2.2 Company snapshot
8.2.3 Operating business segments
8.2.4 Product portfolio
8.2.5 Business performance
8.2.6 Key strategic moves and developments
8.3 Physiocomestoyou
8.3.1 Company overview
8.3.2 Company snapshot
8.3.3 Operating business segments
8.3.4 Product portfolio
8.3.5 Business performance
8.3.6 Key strategic moves and developments
8.4 EURO-THERAPIES
8.4.1 Company overview
8.4.2 Company snapshot
8.4.3 Operating business segments
8.4.4 Product portfolio
8.4.5 Business performance
8.4.6 Key strategic moves and developments
8.5 Institute for Child Development
8.5.1 Company overview
8.5.2 Company snapshot
8.5.3 Operating business segments
8.5.4 Product portfolio
8.5.5 Business performance
8.5.6 Key strategic moves and developments
8.6 Blossoms Physiotherapy
8.6.1 Company overview
8.6.2 Company snapshot
8.6.3 Operating business segments
8.6.4 Product portfolio
8.6.5 Business performance
8.6.6 Key strategic moves and developments
8.7 Pediatric Advanced Therapy
8.7.1 Company overview
8.7.2 Company snapshot
8.7.3 Operating business segments
8.7.4 Product portfolio
8.7.5 Business performance
8.7.6 Key strategic moves and developments
8.8 Chatham Speech and Myo
8.8.1 Company overview
8.8.2 Company snapshot
8.8.3 Operating business segments
8.8.4 Product portfolio
8.8.5 Business performance
8.8.6 Key strategic moves and developments
8.9 Movement Masters Physical Therapy
8.9.1 Company overview
8.9.2 Company snapshot
8.9.3 Operating business segments
8.9.4 Product portfolio
8.9.5 Business performance
8.9.6 Key strategic moves and developments
8.10 Rio Children’s Hospital
8.10.1 Company overview
8.10.2 Company snapshot
8.10.3 Operating business segments
8.10.4 Product portfolio
8.10.5 Business performance
8.10.6 Key strategic moves and developments

LIST OF TABLES
TABLE 1. GLOBAL CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 2. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR PHYSIOTHERAPY, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
TABLE 3. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR PHYSIOTHERAPY, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
TABLE 4. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR SPEECH THERAPY, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
TABLE 5. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR SPEECH THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
TABLE 6. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR OCCUPATIONAL THERAPY, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
TABLE 7. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR OCCUPATIONAL THERAPY, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
TABLE 8. GLOBAL CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 9. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR HOSPITALS AND SPECIALTY CLINICS, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
TABLE 10. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR HOSPITALS AND SPECIALTY CLINICS, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
TABLE 11. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR OTHERS, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
TABLE 12. CRI-DU-CHAT SYNDROME TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
TABLE 13. CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY REGION, 2021-2031 (REVENUE, $THOUSAND)
TABLE 14. NORTH AMERICA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 15. NORTH AMERICA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 16. NORTH AMERICA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
TABLE 17. U.S. CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 18. U.S. CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 19. CANADA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 20. CANADA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 21. MEXICO CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 22. MEXICO CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 23. EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 24. EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 25. EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
TABLE 26. GERMANY CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 27. GERMANY CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 28. FRANCE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 29. FRANCE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 30. UK CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 31. UK CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 32. ITALY CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 33. ITALY CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 34. SPAIN CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 35. SPAIN CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 36. REST OF EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 37. REST OF EUROPE CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 38. ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 39. ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 40. ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
TABLE 41. JAPAN CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 42. JAPAN CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 43. CHINA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 44. CHINA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 45. INDIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 46. INDIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 47. AUSTRALIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 48. AUSTRALIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 49. SOUTH KOREA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 50. SOUTH KOREA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 51. REST OF ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 52. REST OF ASIA-PACIFIC CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 53. LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 54. LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 55. LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY COUNTRY, 2021-2031 (REVENUE, $THOUSAND)
TABLE 56. BRAZIL CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 57. BRAZIL CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 58. SAUDI ARABIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 59. SAUDI ARABIA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 60. SOUTH AFRICA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 61. SOUTH AFRICA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 62. REST OF LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY TREATMENT, 2021-2031 (REVENUE, $THOUSAND)
TABLE 63. REST OF LAMEA CRI-DU-CHAT SYNDROME TREATMENT MARKET, BY END USER, 2021-2031 (REVENUE, $THOUSAND)
TABLE 64.HOPPERS PHYSIO: COMPANY SNAPSHOT
TABLE 65.HOPPERS PHYSIO: OPERATING SEGMENTS
TABLE 66.HOPPERS PHYSIO: PRODUCT PORTFOLIO
TABLE 67.HOPPERS PHYSIO: NET SALES
TABLE 68.HOPPERS PHYSIO: KEY STRATERGIES
TABLE 69.JEEVAM THERAPY: COMPANY SNAPSHOT
TABLE 70.JEEVAM THERAPY: OPERATING SEGMENTS
TABLE 71.JEEVAM THERAPY: PRODUCT PORTFOLIO
TABLE 72.JEEVAM THERAPY: NET SALES
TABLE 73.JEEVAM THERAPY: KEY STRATERGIES
TABLE 74.PHYSIOCOMESTOYOU: COMPANY SNAPSHOT
TABLE 75.PHYSIOCOMESTOYOU: OPERATING SEGMENTS
TABLE 76.PHYSIOCOMESTOYOU: PRODUCT PORTFOLIO
TABLE 77.PHYSIOCOMESTOYOU: NET SALES
TABLE 78.PHYSIOCOMESTOYOU: KEY STRATERGIES
TABLE 79.EURO-THERAPIES: COMPANY SNAPSHOT
TABLE 80.EURO-THERAPIES: OPERATING SEGMENTS
TABLE 81.EURO-THERAPIES: PRODUCT PORTFOLIO
TABLE 82.EURO-THERAPIES: NET SALES
TABLE 83.EURO-THERAPIES: KEY STRATERGIES
TABLE 84.INSTITUTE FOR CHILD DEVELOPMENT: COMPANY SNAPSHOT
TABLE 85.INSTITUTE FOR CHILD DEVELOPMENT: OPERATING SEGMENTS
TABLE 86.INSTITUTE FOR CHILD DEVELOPMENT: PRODUCT PORTFOLIO
TABLE 87.INSTITUTE FOR CHILD DEVELOPMENT: NET SALES
TABLE 88.INSTITUTE FOR CHILD DEVELOPMENT: KEY STRATERGIES
TABLE 89.BLOSSOMS PHYSIOTHERAPY: COMPANY SNAPSHOT
TABLE 90.BLOSSOMS PHYSIOTHERAPY: OPERATING SEGMENTS
TABLE 91.BLOSSOMS PHYSIOTHERAPY: PRODUCT PORTFOLIO
TABLE 92.BLOSSOMS PHYSIOTHERAPY: NET SALES
TABLE 93.BLOSSOMS PHYSIOTHERAPY: KEY STRATERGIES
TABLE 94.PEDIATRIC ADVANCED THERAPY: COMPANY SNAPSHOT
TABLE 95.PEDIATRIC ADVANCED THERAPY: OPERATING SEGMENTS
TABLE 96.PEDIATRIC ADVANCED THERAPY: PRODUCT PORTFOLIO
TABLE 97.PEDIATRIC ADVANCED THERAPY: NET SALES
TABLE 98.PEDIATRIC ADVANCED THERAPY: KEY STRATERGIES
TABLE 99.CHATHAM SPEECH AND MYO: COMPANY SNAPSHOT
TABLE 100.CHATHAM SPEECH AND MYO: OPERATING SEGMENTS
TABLE 101.CHATHAM SPEECH AND MYO: PRODUCT PORTFOLIO
TABLE 102.CHATHAM SPEECH AND MYO: NET SALES
TABLE 103.CHATHAM SPEECH AND MYO: KEY STRATERGIES
TABLE 104.MOVEMENT MASTERS PHYSICAL THERAPY: COMPANY SNAPSHOT
TABLE 105.MOVEMENT MASTERS PHYSICAL THERAPY: OPERATING SEGMENTS
TABLE 106.MOVEMENT MASTERS PHYSICAL THERAPY: PRODUCT PORTFOLIO
TABLE 107.MOVEMENT MASTERS PHYSICAL THERAPY: NET SALES
TABLE 108.MOVEMENT MASTERS PHYSICAL THERAPY: KEY STRATERGIES
TABLE 109.RIO CHILDREN'S HOSPITAL: COMPANY SNAPSHOT
TABLE 110.RIO CHILDREN'S HOSPITAL: OPERATING SEGMENTS
TABLE 111.RIO CHILDREN'S HOSPITAL: PRODUCT PORTFOLIO
TABLE 112.RIO CHILDREN'S HOSPITAL: NET SALES
TABLE 113.RIO CHILDREN'S HOSPITAL: KEY STRATERGIES

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 遠隔リハビリテーションのグローバル市場（2021〜2031）：理学療法、作業療法、言語療法
  • 慢性脳障害治療のグローバル市場2023：作業療法、理学療法、心理療法、言語療法
  • 慢性脳損傷治療の世界市場2023-2029：作業療法、理学療法、心理療法、言語療法
  • 世界のリハビリテーション装置市場2021年-2031年：製品種類別（移動補助器、日常生活補助器、運動装置、身体支持装置）、用途別（理学療法、作業療法、その他）、エンドユーザー別（病院・診療所、リハビリテーションセンター、在宅医療）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(ALD23FB269 )"クリ・デュ・チャット症候群治療のグローバル市場（2021〜2031）：理学療法、言語療法、作業療法" (英文：Cri-du-chat Syndrome Treatment Market By Treatment (Physiotherapy, Speech therapy, Occupational therapy), By End User (Hospitals and specialty clinics, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031)はAllied Market Research社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。